Anti-inflammatory and hypolipemic effects in vitro of simvastatin comparing to epicatechin in patients with type-2 hypercholesterolemia

Food and Chemical Toxicology

Volumn 47, Issue 2, 2009, Pages 393-397

  Franiak Pietryga, I ^a   Koter Michalak, M ^a   Broncel, M ^b   Duchnowicz, Piotr ^a   Chojnowska Jezierska, J ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Epicatechin; Erythrocyte membrane; Hypercholesterolemia; Simvastatin

Indexed keywords

CHOLESTEROL; EPICATECHIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; LIPID PEROXIDATION; MEMBRANE FLUIDITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CATECHIN; CHOLESTEROL; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; HUMANS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MEMBRANE FLUIDITY; MEMBRANE LIPIDS; MIDDLE AGED; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 58149503020     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.11.027     Document Type: Article

References (33)

1. Aviram M., Keidar S., and Brook G.J. Dual effect of lovastatin and simvastatin on LDL-macrophage interaction. Eur. J. Clin. Chem. Clin. Biochem. 29 (1991) 657-664
2. Aviram M., Hussein O., Rosenblat M., Schlesinger S., Hayek T., and Keidar S. Interactions of platelets, macrophages and lipoproteins in hypercholesterolemia, antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J. Cardiovasc. Pharmacol. 31 (1998) 39-45
3. Aviram M., Rosenblat M., Bisgaier C.L., and Newton R.S. Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138 (1998) 271-280
4. Beaumont J.L., Carlson L.A., Cooper G.R., Fejfar Z., Fredrickson D.S., and Strasser T. Classification of hyperlipidemia and hyperlipoproteinemia. Bull. World Health Organ. 43 (1970) 891-915
5. Bellosta S., Ferri N., Bernini F., Paoletti R., and Corsini A. Non-lipid-related effects of statins. Ann. Med. 32 (2000) 164-176
6. Bernini F., Didoni G., Bonfadini G., Bellosta S., and Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis 104 (1993) 19-26
7. Bokoch G.M., and Pritz V. Isoprenoid metabolism is required for stimulation of the respiratory burst. Oxidase of HL-60 cells. J. Clin. Invest. 89 (1992) 402-408
8. Broncel M., Chojnowska-Jezierska J., Koter-Michalak M., and Franiak I. Erythrocyte fluidity in patients with hyperlipidemia during statins therapy. Pol. Arch. Med. Wewn. 113 (2005) 531-537
9. Ceylan A., Karasu C., Aktan F., Güven C., Can B., and Ozansoy G. Effects of simvastatin treatment on oxidant/antioxidant state and ultrastructure of diabetic rat myocardium. Gen. Physiol. Biophys. 22 (2003) 535-547
10. Cirico T.L., and Omaye S.T. Additive or synergetic effects of phenolic compounds on human low density lipoprotein oxidation. Food Chem. Toxicol. 4 (2006) 510-516
11. Corsini A., Mazzotti M., Raiteri M., Soma M.R., Gabbiani G., Fumagalli R., and Paoletti R. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with HMG-CoA reductase. Atherosclerosis 101 (1993) 117-125
12. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insight into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84 (1999) 413-428
13. Davignon J., and Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr. Opin. Lipidol. 10 (1999) 543-559
14. Feussner G. HMG-CoA reductase inhibitors. Curr. Opin. Lipidol. 5 (1994) 59-68
15. Girona J., La Ville A.E., Sola R., Plana N., and Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am. J. Cardiol. 83 (1999) 846-851
16. Giroux L.M., Davignon J., and Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte derived macrophages. Biochim. Biophys. Acta 1165 (1993) 335-338
17. Gmiński J., and Wojakowski W. The antiatherosclerotic actions of HMG-CoA reductase inhibitors. Przegla{ogonek}d Lekarski 54 11 (1997) 782-787
18. de Grot H. Reactive oxygen species in tissue injury. Hepatogastroenterology 41 (1994) 328-332
19. Hamaishi K., Kojma R., and Ito M. Anti-ulcer effect of tea catechin in rats. Biol. Pharm. Bull. 11 (2006) 2206-2213
20. Kerry N.L., and Abbey M. Red wine and fractionated phenolic compounds prepared from red wine inhibit low density lipoprotein oxidation in vitro. Atherosclerosis 135 (1997) 93-102
21. Kimura M., Kurose I., Russel J., and Granger D.N. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 1521-1526
22. Klyszejko-Stefanowicz, L., 1995. Cytobiochemia. Wydawnictwo Naukowe PWN.
23. Koo S.I., and Noh S.K. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J. Nutr. Biochem. 18 (2007) 179-183
24. Koter M., Broncel M., Chojnowska-Jezierska J., Klikczyńska K., and Franiak I. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia. Eur. J. Clin. Pharm. 58 (2002) 501-506
25. Koter M., Franiak I., Broncel M., and Chojnowska-Jezierska J. The effects of simvastatin and pravastatin on peroxydation of the erythrocyte plasma membrane lipids in patients with type-2 hypercholesterolemia. Can. J. Physiol. Pharmacol. 81 (2003) 485-492
26. Middleton E.J. Effect of plan flavonoids on immune and inflammatory cell function. Adv. Exp. Med. Biol. 439 (1998) 175-182
27. Nijveldt R.J., van Nood E., van Hoorn D.E.C., Boelens P.G., van Norren K., and van Leeuwen P.A.M. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74 (2001) 418-425
28. Ozdemirler G., Küçük S., Orhan Y., Aykaç-Toker G., and Uysal M. Lipid and protein oxidation in erythrocyte membranes of hypercholesterolemic subjects. Clin. Biochem. 34 (2001) 335-339
29. Rodriguez-Vico F., Martinez-Cayuela M., Zafra M.F., Garcia-Peregrin E., and Ramirez H. A procedure for the simultaneous determination of lipid and protein in biomembranes and other biological samples. Lipids 26 (1991) 77-80
30. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
31. Stocks J., and Dormandy T.L. The autoxidation of human red cell lipids induced by hydrogen peroxide. Br. J. Haematol. 20 (1971) 95-111
32. Suzumura K., Yasuhara M., Tanaka K., and Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxyl-3methylglutaryl coenzyme A (HMG CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem. Pharmacol. 57 (1999) 697-703
33. Thallinger C., Urbauer E., Lackner E., Graselli U., Kostner K., Wolzt M., and Joukhadar C. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Int. J. Clin. Pharmacol. Ther. 43 (2005) 551-557